Shionogi & Co., Ltd. is a major player in the Healthcare sector, specifically within the Drug Manufacturers industry. The company currently commands a significant market capitalization of JPY 2.49 Trillion, reflecting its established presence in the global pharmaceutical market. Recent short-term performance has been positive, with a 3.88% gain over the last seven days, bringing the current price to JPY 2,928.50.

Our technical analysis for Shionogi results in a neutral Hold rating with a total score of 0. This rating stems from conflicting signals across different timeframes. A significant bearish indicator is that the current price is trading below its 200-day Simple Moving Average (JPY 2,998.09), which points to a potential long-term downtrend. However, bullish short-term momentum is evident from a positive MACD histogram and an On-Balance Volume (OBV) that is above its moving average, indicating recent accumulation pressure. The trend strength is weak, with an ADX of only 12.66, and the RSI (56.95) is in neutral territory, offering no strong directional bias at this time.

This technical 'Hold' rating finds some alignment with the fundamental context, which presents a mixed but cautious outlook. The company's P/E ratio of 12.15 appears reasonable for its sector, and a notable dividend of JPY 260.0 per share adds to its appeal for income-focused investors. However, a key element of uncertainty is the lack of available recent earnings data, with the last reported EPS surprise being null. Furthermore, the next scheduled earnings report is listed for 29/10/2026, which is unusually far in the future. Given the conflict between long-term bearish and short-term bullish technicals, coupled with this fundamental uncertainty, a 'Hold' position is warranted until a clearer directional trend emerges.